Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Nkongolo, Shirin [VerfasserIn]   i
 Nußbaum, Lea [VerfasserIn]   i
 Lempp, Florian A. [VerfasserIn]   i
 Wodrich, Harald [VerfasserIn]   i
 Urban, Stephan [VerfasserIn]   i
 Ni, Yi [VerfasserIn]   i
Titel:The retinoic acid receptor (RAR) α-specific agonist Am80 (tamibarotene) and other RAR agonists potently inhibit hepatitis B virus transcription from cccDNA
Verf.angabe:Shirin Nkongolo, Lea Nußbaum, Florian A. Lempp, Harald Wodrich, Stephan Urban, Yi Ni
E-Jahr:2019
Jahr:21 April 2019
Umfang:10 S.
Teil:volume:168
 year:2019
 pages:146-155
 extent:10
Fussnoten:Gesehen am 17.05.2021
Titel Quelle:Enthalten in: Antiviral research
Ort Quelle:Amsterdam [u.a.] : Elsevier Science, 1981
Jahr Quelle:2019
Band/Heft Quelle:168(2019), Seite 146-155
ISSN Quelle:1872-9096
Abstract:Chronic infection with the human Hepatitis B virus (HBV) is a major global health problem. Hepatitis D virus (HDV) is a satellite of HBV that uses HBV envelope proteins for cell egress and entry. Using infection systems encoding the HBV/HDV receptor human sodium taurocholate co-transporting polypeptide (NTCP), we screened 1181 FDA-approved drugs applying markers for interference for HBV and HDV infection. As one primary hit we identified Acitretin, a retinoid, as an inhibitor of HBV replication and HDV release. Based on this, other retinoic acid receptor (RAR) agonists with different specificities were found to interfere with HBV replication, verifying that the retinoic acid receptor pathway regulates replication. Of the eight agonists investigated, RARα-specific agonist Am80 (tamibarotene) was most active. Am80 reduced secretion of HBeAg and HBsAg with IC50s<10nM in differentiated HepaRG-NTCP cells. Similar effects were observed in primary human hepatocytes. In HepG2-NTCP cells, profound Am80-mediated inhibition required prolonged treatment of up to 35 days. Am80 treatment of cells with an established HBV cccDNA pool resulted in a reduction of secreted HBsAg and HBeAg, which correlated with reduced intracellular viral RNA levels, but not cccDNA copy numbers. The effect lasted for >12 days after removal of the drug. HBV genotypes B, D, and E were equally inhibited. By contrast, Am80 did not affect HBV replication in transfected cells or HepG2.2.15cells, which carry an integrated HBV genome. In conclusion, our results indicate a persistent inhibition of HBV transcription by Am80, which might be used for drug repositioning.
DOI:doi:10.1016/j.antiviral.2019.04.009
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.1016/j.antiviral.2019.04.009
 Volltext: https://www.sciencedirect.com/science/article/pii/S0166354218307587
 DOI: https://doi.org/10.1016/j.antiviral.2019.04.009
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Acitretin
 Drug screening
 Hepatitis B virus
 Hepatitis delta virus
 Retinoic acid receptor
 Tamibarotene
K10plus-PPN:1757933824
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68738294   QR-Code
zum Seitenanfang